4820 Richard Road South West Suite 300 Calgary AB T3E 6L1 CAN P: 403-254-9252 F: 403-256-8495 https://www.resverlogix.com
Sectors & Indices
Sector
Industry
Employees
Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Key Executives
Name
Title
Michael Sweeney
Senior VP, Divisional
A. Brad Cann
CFO
Donald J. McCaffrey
CEO/Co-Founder/Director/President/Secretary/Chairman of the Board